 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| GC012 / Gracell, GC022F / Gracell
Clinical: Indeed, it seems they both proliferate (GC012 & GC022). Though it's yet another variability parameter that will probably play negatively in some patients. (Twitter) - Dec 6, 2020
- | GC022F / AstraZeneca
New P1/2 trial: Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 12, 2020
P1/2, N=18, Not yet recruiting, Sponsor: He Huang
- SENL-B19 / Hebei Senlang Biotechnology
[VIRTUAL] Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL) (Channel 13 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1408;
P1
All patients received a conditioning regimen of IV fludarabine (25mg/m2/d) and cyclophosphamide (250mg/m2/d) for 3 days prior to GC022F infusion...Our clinical data demonstrate that GC022F is safe and efficacious in treating patients with CD19+CD22+ B-ALL. More data on additional patients and longer observation time are needed to further evaluate CD19/CD22 dual FasTCAR-T cell product.
- | GC022F / AstraZeneca
New P1 trial, CAR T-Cell Therapy: A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL (clinicaltrials.gov) - Jun 1, 2020
P1, N=18, Not yet recruiting, Sponsor: Hebei Yanda Ludaopei Hospital
- | GC022F / Gracell
Enrollment open, CAR T-Cell Therapy: A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (clinicaltrials.gov) - May 26, 2020
P1, N=18, Recruiting, Sponsor: Hebei Yanda Ludaopei Hospital
More data on additional patients and longer observation time are needed to further evaluate CD19/CD22 dual FasTCAR-T cell product. Not yet recruiting --> Recruiting
- | GC022F / Gracell
New P1 trial, CAR T-Cell Therapy: A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (clinicaltrials.gov) - Oct 15, 2019
P1, N=18, Not yet recruiting, Sponsor: Hebei Yanda Ludaopei Hospital
- | GC022F / Gracell
New P1 trial, CAR T-Cell Therapy: A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (clinicaltrials.gov) - Jan 31, 2019
P1, N=20, Recruiting, Sponsor: Hebei Yanda Ludaopei Hospital